Volume 58, Issue 3, Pages (September 2000)

Slides:



Advertisements
Similar presentations
Volume 66, Issue 1, Pages (July 2004)
Advertisements

Volume 63, Issue 6, Pages (June 2003)
Volume 65, Issue 1, Pages (January 2004)
Osteopontin expression in human crescentic glomerulonephritis
Volume 82, Issue 6, Pages (September 2012)
Volume 68, Issue 6, Pages (December 2005)
Volume 64, Issue 1, Pages (July 2003)
Volume 64, Issue 2, Pages (August 2003)
Volume 68, Issue 5, Pages (November 2005)
Volume 55, Issue 5, Pages (May 1999)
Volume 58, Issue 6, Pages (December 2000)
TGF-β isoforms in renal fibrogenesis
Volume 56, Issue 3, Pages (September 1999)
Volume 63, Issue 6, Pages (June 2003)
Volume 75, Issue 9, Pages (May 2009)
Volume 61, Issue 6, Pages (June 2002)
Volume 54, Issue 3, Pages (September 1998)
Volume 63, Issue 4, Pages (April 2003)
The intrarenal renin-angiotensin system in hypertension
Volume 60, Issue 3, Pages (September 2001)
Volume 68, Issue 1, Pages (July 2005)
Volume 59, Issue 5, Pages (May 2001)
Volume 59, Issue 4, Pages (April 2001)
Hiroyuki Yanagisawa, Nobuyuki Yamazaki, Gen Sato, Osamu Wada 
Volume 63, Issue 5, Pages (May 2003)
Hepatocyte growth factor suppresses interstitial fibrosis in a mouse model of obstructive nephropathy  Shinya Mizuno, Kunio Matsumoto, Toshikazu Nakamura 
Prenatal programming of adult hypertension in the rat
Volume 68, Issue 6, Pages (December 2005)
Mohammed S. Razzaque, Ph.D., Takashi Taguchi  Kidney International 
Volume 57, Issue 3, Pages (March 2000)
Isotretinoin alleviates renal damage in rat chronic glomerulonephritis
Volume 64, Issue 4, Pages (October 2003)
Volume 63, Issue 2, Pages (February 2003)
Volume 53, Issue 5, Pages (May 1998)
Volume 62, Issue 2, Pages (August 2002)
Volume 62, Issue 3, Pages (September 2002)
Volume 55, Issue 2, Pages (February 1999)
Volume 57, Issue 3, Pages (March 2000)
Volume 92, Issue 3, Pages (September 2017)
Volume 61, Issue 1, Pages (January 2002)
Local delivery of angiotensin receptor blocker into the kidney ameliorates progression of experimental glomerulonephritis  J. Mahmood, F. Khan, S. Okada,
Volume 64, Issue 3, Pages (September 2003)
Volume 64, Issue 1, Pages (July 2003)
Volume 62, Issue 3, Pages (September 2002)
Volume 66, Issue 5, Pages (November 2004)
Volume 66, Issue 1, Pages (July 2004)
Effect of nitric oxide modulation on TGF-β1 and matrix proteins in chronic cyclosporine nephrotoxicity  Fuad S. Shihab, Hong Yi, William M. Bennett, Takeshi.
Volume 63, Issue 1, Pages (January 2003)
Volume 54, Issue 4, Pages (October 1998)
B. Li, T. Morioka, M. Uchiyama, T. Oite  Kidney International 
Volume 71, Issue 9, Pages (May 2007)
Volume 82, Issue 3, Pages (August 2012)
Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis  H.-C. Yang, L.-J. Ma, J. Ma, A.B. Fogo 
Volume 65, Issue 6, Pages (June 2004)
Robert L. Chevalier, Barbara A. Thornhill, Alice Y. Chang 
Contribution of tubular injury to loss of remnant kidney function
Volume 65, Issue 6, Pages (June 2004)
Volume 69, Issue 7, Pages (April 2006)
Volume 58, Issue 5, Pages (November 2000)
Volume 58, Issue 4, Pages (October 2000)
Calcium channel blockers, either amlodipine or mibefradil, ameliorate renal injury in experimental diabetes  Guorong Ma, Terri J. Allen, Mark E. Cooper,
Volume 65, Issue 2, Pages (February 2004)
T-PA promotes glomerular plasmin generation and matrix degradation in experimental glomerulonephritis  Masashi Haraguchi, Wayne A. Border, Yufeng Huang,
The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury?  Richard E. Gilbert, Mark E. Cooper  Kidney.
J. Ma, A. Weisberg, J.P. Griffin, D.E. Vaughan, A.B. Fogo, N.J. Brown 
Volume 65, Issue 6, Pages (June 2004)
Volume 65, Issue 1, Pages (January 2004)
Renoprotection with vitamin D: Specific for diabetic nephropathy?
Volume 70, Issue 1, Pages (July 2006)
Volume 75, Issue 2, Pages (January 2009)
Presentation transcript:

Volume 58, Issue 3, Pages 1219-1227 (September 2000) Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo  Nancy J. Brown, Shinya Nakamura, Lijun Ma, Ikuko Nakamura, Ellen Donnert, Michael Freeman, Douglas E. Vaughan, Agnes B. Fogo  Kidney International  Volume 58, Issue 3, Pages 1219-1227 (September 2000) DOI: 10.1046/j.1523-1755.2000.00277.x Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 1 Systolic blood pressure (SBP) measured by tail cuff plethysmography 12 weeks following radiation or sham radiation in nonradiated (N), placebo-treated radiated (R + P), spironolactone-treated radiated (R + SP), angiotensin type 1 receptor antagonist (AT1RA)-treated radiated (R + AT1RA), and spironolactone + AT1RA-treated radiated (R + SP + AT1RA) rats. Kidney International 2000 58, 1219-1227DOI: (10.1046/j.1523-1755.2000.00277.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 2 Twenty-four–hour urine protein excretion 12 weeks following radiation or sham radiation in nonradiated (N), placebo-treated radiated (R + P), spironolactone-treated radiated (R + SP), AT1RA-treated radiated (R + AT1RA), and spironolactone + AT1RA-treated radiated (R + SP + AT1RA) rats. Kidney International 2000 58, 1219-1227DOI: (10.1046/j.1523-1755.2000.00277.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 3 Sclerosis index assessed in kidneys obtained from placebo-treated (R + P) radiated, spironolactone-treated radiated (R + SP), AT1RA-treated radiated (R + AT1RA), and spironolactone + AT1RA-treated radiated (R + SP + AT1RA) rats sacrificed at 12 weeks. The sclerosis index was calculated as outlined in the text. Kidney International 2000 58, 1219-1227DOI: (10.1046/j.1523-1755.2000.00277.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 4 Expression of plasminogen activator inhibitor-1 (PAI-1) mRNA, normalized for GAPDH mRNA expression, measured in kidneys obtained from placebo-treated radiated (R + P), spironolactone-treated radiated (R + SP), AT1RA-treated radiated (R + AT1RA), and spironolactone + AT1RA-treated radiated (R + SP + AT1RA) rats sacrificed at 12 weeks. Kidney International 2000 58, 1219-1227DOI: (10.1046/j.1523-1755.2000.00277.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 5 Photomicrographs of kidney sections from placebo-treated and spironolactone-treated radiated rats. At 12 weeks, the kidney from placebo-treated radiated rats showed moderate tubulointerstitial damage and glomerulosclerosis (A). In spironolactone-treated rats, tubulointerstitial damage and glomerulosclerosis were ameliorated, as illustrated by decreased collagen staining (B; Masson stain A and B, ×100). PAI-1 immunostaining was increased diffusely in the tubulointerstitium and was accentuated in areas of segmental sclerosis in placebo-treated radiated rats (C, ×400). By in situ hybridization (E, ×400) PAI-1 mRNA expression exhibited a similar distribution, with accentuation in sclerotic glomeruli in placebo-treated radiated rats. In areas of injury, PAI-1 mRNA signal was present in mesangial areas and glomerular visceral epithelial cells (arrows). There was no signal after in situ hybridization with sense probes (data not shown). In the spironolactone-treated rats, PAI-1 immunostaining (D, ×200) and mRNA (F, ×200) were decreased in both the tubular interstitium and in glomeruli (arrow). By in situ hybridization, transforming growth factor-β (TGF-β) mRNA was mildly and diffusely increased with occasional accentuation in the glomeruli of placebo-treated radiated rats (G, ×400). TGF-β mRNA was mildly attenuated by treatment with spironolactone (H, ×400). Kidney International 2000 58, 1219-1227DOI: (10.1046/j.1523-1755.2000.00277.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 6 Relationship between the sclerosis index and plasminogen activator inhibitor 1 (PAI-1) immunostaining for glomeruli from all radiated rats. Symbols are: (•) N = 1; (▴) N = 10; (▪) N = 100. Kidney International 2000 58, 1219-1227DOI: (10.1046/j.1523-1755.2000.00277.x) Copyright © 2000 International Society of Nephrology Terms and Conditions